Skip to main content
Journal cover image

Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study.

Publication ,  Journal Article
Wang, SM; Li, Y; Nash, A; Ren, Y; Thomas, SM; Francescatti, AB; Barber, A; Lynch, T; Frank, ES; Grimm, LJ; Thompson, AM; Partridge, AH ...
Published in: Br J Surg
August 30, 2024

BACKGROUND: Breast-conserving surgery alone, breast-conserving surgery with adjuvant radiation treatment, and mastectomy are guideline-concordant treatments for ductal carcinoma in situ. The aim of this study was to compare survival outcomes between these treatment options. METHODS: A stratified random sample of patients diagnosed with pure ductal carcinoma in situ between 2008 and 2014 was selected from 1330 sites in the USA. Data on diagnosis, treatment, and follow-up were abstracted by local cancer registrars. Population-averaged marginal estimates of disease-specific survival and overall survival for breast-conserving surgery alone, breast-conserving surgery with radiation treatment, and mastectomy were obtained by combining sampling and overlap weights. RESULTS: A total of 18 442 women were included, with a median follow-up of 67.8 (interquartile range 46.1-93.5) months. A total of 35 women died from breast cancer, at a median age of 62 (interquartile range 50-74) years. Population-averaged 8-year rates of disease-specific survival were 99.6% or higher for all treatment groups, with no significant differences between groups (breast-conserving surgery alone versus breast-conserving surgery with radiation treatment, HR 1.19 (95% c.i. 0.29 to 4.85); and mastectomy versus breast-conserving surgery with radiation treatment, HR 1.74 (95% c.i. 0.53 to 5.72). There was no difference in overall survival between the patients who underwent a mastectomy and the patients who underwent breast-conserving surgery with radiation treatment (HR 1.09 (95% c.i. 0.83 to 1.43)). Patients who underwent breast-conserving surgery alone had lower overall survival compared with the patients who underwent breast-conserving surgery with radiation treatment (HR 1.29 (95% c.i. 1.00 to 1.67)). This survival difference vanished for all but one subgroup, namely patients less than 65 years (HR 1.86 (95% c.i. 1.15 to 3.00)). CONCLUSION: There was no statistically significant difference in disease-specific survival between women operated with breast-conserving surgery alone, breast-conserving surgery with radiation treatment, or mastectomy for ductal carcinoma in situ. Given the low absolute risk of disease-specific mortality, these results provide confidence in offering individualized locoregional treatment without fear of compromising survival.

Duke Scholars

Published In

Br J Surg

DOI

EISSN

1365-2168

Publication Date

August 30, 2024

Volume

111

Issue

9

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surgery
  • Radiotherapy, Adjuvant
  • Middle Aged
  • Mastectomy, Segmental
  • Mastectomy
  • Humans
  • Female
  • Carcinoma, Intraductal, Noninfiltrating
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, S. M., Li, Y., Nash, A., Ren, Y., Thomas, S. M., Francescatti, A. B., … Ryser, M. D. (2024). Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Br J Surg, 111(9). https://doi.org/10.1093/bjs/znae198
Wang, Sabrina M., Yan Li, Amanda Nash, Yi Ren, Samantha M. Thomas, Amanda B. Francescatti, Anne Barber, et al. “Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study.Br J Surg 111, no. 9 (August 30, 2024). https://doi.org/10.1093/bjs/znae198.
Wang SM, Li Y, Nash A, Ren Y, Thomas SM, Francescatti AB, et al. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Br J Surg. 2024 Aug 30;111(9).
Wang, Sabrina M., et al. “Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study.Br J Surg, vol. 111, no. 9, Aug. 2024. Pubmed, doi:10.1093/bjs/znae198.
Wang SM, Li Y, Nash A, Ren Y, Thomas SM, Francescatti AB, Barber A, Lynch T, Frank ES, Grimm LJ, Thompson AM, Partridge AH, Hyslop T, Hwang ES, Ryser MD. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Br J Surg. 2024 Aug 30;111(9).
Journal cover image

Published In

Br J Surg

DOI

EISSN

1365-2168

Publication Date

August 30, 2024

Volume

111

Issue

9

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surgery
  • Radiotherapy, Adjuvant
  • Middle Aged
  • Mastectomy, Segmental
  • Mastectomy
  • Humans
  • Female
  • Carcinoma, Intraductal, Noninfiltrating